In a report released yesterday, Sarah James from Piper Jaffray reiterated a Buy rating on Humana Inc (NYSE: HUM), with a price target of $355. The company’s shares opened today at $318.60, close to its 52-week high of $327.44.
According to TipRanks.com, James is a 5-star analyst with an average return of 24.6% and a 92.0% success rate. James covers the Services sector, focusing on stocks such as Encompass Health Corporation, WellCare Health Plans, and Molina Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Humana Inc with a $337.14 average price target, which is a 5.8% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $350 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $327.44 and a one-year low of $231.90. Currently, Humana Inc has an average volume of 629.2K.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2018, Brian Leclaire, the CIO of HUM sold 5,165 shares for a total of $1,581,213.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana Inc. is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.
